Physical Therapy to Prevent Osteopenia in Preterm Infants

Sponsor
Galaad Torró Ferrero (Other)
Overall Status
Completed
CT.gov ID
NCT04356807
Collaborator
(none)
101
3
3
53
33.7
0.6

Study Details

Study Description

Brief Summary

To determine whether reflex locomotion therapy is effective for the prevention of osteopenia in preterm infants and compare its effectiveness over other physiotherapeutic methods like passive joint mobilizations and massage

Condition or Disease Intervention/Treatment Phase
  • Procedure: Reflex Locomotion Therapy
  • Procedure: Passive Joint Mobilizations
  • Procedure: Massage
N/A

Detailed Description

Premature infants have smaller and low bone mineralization compared with term infants bones, since 80% of calcium uptake occurs at the end of pregnancy. Passive Physiotherapy has been effective in the treatment of osteopenia. Active mobilizations implemented by the baby itself, may be more effective than passive, as they cause muscle contraction from the Central Nervous System (CNS). Reflex locomotion therapy (RLT), stimulates CNS causing muscle contraction so it may be effective in the treatment of osteopenia in premature.

Objectives: To determine whether RLT is effective for the prevention of osteopenia in preterm infants and compare its effectiveness over other physiotherapeutic methods.

Methodology: Our study is a multicentre randomized clinical trial, with 90 children less than 34 weeks of gestational age, divided into three treatment groups, one will receive RLT, another will be treated with passive joint mobilizations with articular pressure; and last one will be done massage techniques. The treatment will last for one month, for the three groups. We intend to measure changes in mineralization, bone formation, and bone resorption, and anthropometry.

Study Design

Study Type:
Interventional
Actual Enrollment :
101 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Masking Description:
Care Provider and Outcomes Assessor are masked to the objectives of the study
Primary Purpose:
Prevention
Official Title:
Effect of Physiotherapy on the Promotion of Bone Mineralization in Preterm Infants
Actual Study Start Date :
Feb 1, 2016
Actual Primary Completion Date :
Jul 1, 2020
Actual Study Completion Date :
Jul 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Reflex Locomotion Therapy

during 15 minutes once a day five days a week

Procedure: Reflex Locomotion Therapy
The exercises corresponding to the motor complexes of the 1st phase of the rolling reflex and the original creeping reflex were performed, dedicating one minute to each side and performing two repetitions in each session.

Experimental: Passive Joint Mobilizations

during 15 minutes once a day five days a week

Procedure: Passive Joint Mobilizations
Passive Joint Mobilizations with articular pressure described by Moyer-Mileur, et al. 1995 and modified by Vignochi, et al. 2008

Placebo Comparator: Massage

during 15 minutes once a day five days a week

Procedure: Massage
Soft massage with soft pressures in limbs, tactile stimulation and no motion.

Outcome Measures

Primary Outcome Measures

  1. Change in Tibial Speed of Sound [Change measurement: Pre treatment (baseline), at two weeks of treatment and after four weeks of treatment (end of the treatment)]

    In order to measure bone mineralization, we used the tibial sound velocity test, using for that purpose a quantitative ultrasound device. It was measured on the left tibia in its lower third, while keeping the knee flexed at a 90 degree angle. The measurement point was made perpendicular to the direction of the bone. Three to five consecutive measurements were made, after which the average of these measurements was calculated to have one unique measure in m/s.

  2. Change in Serum biomarkers of Bone-specific phosphatase markers [Change measurement: Pre treatment (baseline), and after four weeks of treatment (end of the treatment)]

    N-telopeptides from collagen bonds from serum

  3. Change in Serum biomarkers of osteocalcin markers [Change measurement: Pre treatment (baseline), and after four weeks of treatment (end of the treatment)]

    osteocalcin markers

  4. Change in Serum biomarkers of Beta-cross Laps. [Change measurement: Pre treatment (baseline), and after four weeks of treatment (end of the treatment)]

    Beta-cross Laps.

  5. Change in Urine biomarkers of N-telopeptides from collagen bonds [Change measurement: Pre treatment (baseline), at two weeks of treatment and after four weeks of treatment (end of the treatment)]

    N-telopeptides from collagen bonds

Secondary Outcome Measures

  1. Change in Height [Change measurement: Pre treatment (baseline), at two weeks of treatment and after four weeks of treatment (end of the treatment)]

    For anthropometry, height in cm were collected

  2. Change in Weight [Change measurement: Pre treatment (baseline), at two weeks of treatment and after four weeks of treatment (end of the treatment)]

    measurements of weight in grams were collected

  3. Change in Head circumference [Change measurement: Pre treatment (baseline), at two weeks of treatment and after four weeks of treatment (end of the treatment)]

    For anthropometry, measurements of head circumference in cm were collected

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 34 Weeks
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Preterm infants

  • 26 to 34 weeks of gestational age

  • Admitted in neonates

  • Hemodynamically stable

  • Complete enteral nutrition

  • Parents or guardians signed an informed consent authorizing the participation of the baby in this study.

Exclusion Criteria:
  • Neurological disorders

  • Mechanical ventilation

  • Bronchopulmonary dysplasia

  • Congenital malformations

  • Metabolic diseases

  • Genetic diseases

  • Intraventricular hemorrhage III-IV,

  • Diuretic medication or corticosteroids

  • Bone fractures at the time of inclusion.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital General Universitario de Elche Elche Alicante Spain 03203
2 Hospital Torrecárdenas de Almería Almería Spain 04009
3 Hospital Clínico Universitario Virgen de la Arrixaca Murcia Spain 30120

Sponsors and Collaborators

  • Galaad Torró Ferrero

Investigators

  • Principal Investigator: Galaad Torró-Ferrero, MSc, Universidad de Murcia

Study Documents (Full-Text)

More Information

Publications

Responsible Party:
Galaad Torró Ferrero, Principal Investigator, Universidad de Murcia
ClinicalTrials.gov Identifier:
NCT04356807
Other Study ID Numbers:
  • Fisio-Osteopenia
First Posted:
Apr 22, 2020
Last Update Posted:
Dec 1, 2020
Last Verified:
Nov 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Galaad Torró Ferrero, Principal Investigator, Universidad de Murcia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 1, 2020